Novartis AG and Novavax, Inc.'s Experimental Bird Flu Vaccines Show Promise In Early Trials

The first human tests of experimental vaccines against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, has produced protective antibodies in the vast majority of recipients. Encouraging results in early-stage trials were announced for separate vaccines from Swiss drugmaker Novartis and Novavax, a biotech company based in Rockville, Maryland.

Help employers find you! Check out all the jobs and post your resume.